Chongqing Zhifei Biological Products Co (300122) Q3 2026 earnings summary

Executive summary

• Q3 revenue was ¥2.515B, down 7.40% YoY; net profit attributable to shareholders was ¥125.3M, up 117.36% YoY.

• 9M revenue was ¥6.539B, down 14.46% YoY; net loss attributable to shareholders narrowed to ¥683.3M from ¥1.328B.

Financial highlights

• 9M adjusted net loss attributable to shareholders was ¥687.1M, narrowing 49.04% YoY; Q3 adjusted net profit was ¥119.3M, up 116.44% YoY.

• 9M consolidated net loss was ¥705.0M, versus ¥1.341B a year earlier; operating loss was ¥858.1M.

• 9M asset impairment line was a positive ¥210.3M, versus negative ¥119.7M in the prior period; inventory impairment provisions decreased.

Key financial ratios and metrics

• Basic and diluted EPS were ¥0.0523 for Q3, each up 117.35% YoY; 9M EPS was -¥0.2854, an improvement of 48.55% YoY.

• Total assets were ¥27.132B at quarter-end, down 14.46% from year-end; shareholders’ equity was ¥15.157B, down 4.31%.